A new high-throughput method for simultaneous detection of drug resistance associated mutations in Plasmodium vivax dhfr, dhps and mdr1 genes

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Barnadas, Céline ^a,b   Kent, David ^c   Timinao, Lincoln ^a   Iga, Jonah ^a   Gray, Laurie R ^d   Siba, Peter ^a   Mueller, Ivo ^a,b,e   Thomas, Peter J ^c   Zimmerman, Peter A ^d  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; MULTIDRUG RESISTANCE PROTEIN 1; MDR1 PROTEIN, PLASMODIUM VIVAX; MULTIDRUG RESISTANCE PROTEIN; PROTOZOAL DNA; PROTOZOAL PROTEIN;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CODON; ENZYME ASSAY; FLUORESCENCE ANALYSIS; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; HAPLOTYPE; HIGH THROUGHPUT SCREENING; PAPUA NEW GUINEA; PLASMODIUM VIVAX; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; EVALUATION; GENETICS; HUMAN; INFANT; ISOLATION AND PURIFICATION; METHODOLOGY; MUTATION; PARASITOLOGY; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD;

CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DNA, PROTOZOAN; DRUG RESISTANCE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFANT; MALARIA, VIVAX; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; PAPUA NEW GUINEA; PARASITIC SENSITIVITY TESTS; PLASMODIUM VIVAX; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTOZOAN PROTEINS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 80053172537     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-282     Document Type: Article

References (41)

1. Mapping the global extent of malaria in 2005. Guerra CA, Snow RW, Hay SI, Trends Parasitol 2006 22 353 358 10.1016/j.pt.2006.06.006 16798089 (Pubitemid 44108760)
2. The global distribution and population at risk of malaria: past, present, and future. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW, Lancet Infect Dis 2004 4 327 336 10.1016/S1473-3099(04)01043-6 15172341 (Pubitemid 38692697)
3. Cerebral involvement in benign tertian malaria. Beg MA, Khan R, Baig SM, Gulzar Z, Hussain R, Smego RA Jr, Am J Trop Med Hyg 2002 67 230 232 12408660 (Pubitemid 35178345)
4. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I, PLoS Med 2008 5 127 10.1371/journal.pmed.0050127 18563961 (Pubitemid 351919109)
5. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA, Lancet Infect Dis 2009 9 555 566 10.1016/S1473-3099(09)70177-X 19695492
6. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Barcus MJ, Basri H, Picarima H, Manyakori C, Elyazar I, Bangs MJ, Maguire JD, Baird JK, Am J Trop Med Hyg 2007 77 984 991 17984364 (Pubitemid 351837852)
7. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Baird JK, Basri H, Bangs MJ, Subianto B, Patchen LC, Hoffman SL, Am J Trop Med Hyg 1991 44 547 552 1676566
8. Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia. Fryauff DJ, Tuti S, Mardi A, Masbar S, Patipelohi R, Leksana B, Kain KC, Bangs MJ, Richie TL, Baird JK, Am J Trop Med Hyg 1998 59 513 518 9790420 (Pubitemid 28480701)
9. An unusual case of multidrug-resistant Plasmodium vivax malaria in Mumbai (Bombay), India. Kshirsagar NA, Gogtay NJ, Rajgor D, Dalvi SS, Wakde M, Ann Trop Med Parasitol 2000 94 189 190 10.1080/00034980057536 10827874 (Pubitemid 30209445)
10. Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Myat Phone K, Myint O, Myint L, Thaw Z, Kyin Hla A, Nwe Nwe Y, Trans R Soc Trop Med Hyg 1993 87 6 687 10.1016/0035-9203(93)90294-Z 8296378
11. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Phillips EJ, Keystone JS, Kain KC, Clin Infect Dis 1996 23 1171 1173 10.1093/clinids/23.5. 1171 8922821 (Pubitemid 126782788)
12. Plasmodium vivax resistance to chloroquine? Rieckmann KH, Davis DR, Hutton DC, Lancet 1989 2 1183 1184 2572903 (Pubitemid 19275451)
13. Chloroquine-resistant Plasmodium vivax malaria in Peru. Ruebush TK, Zegarra J, Cairo J, Andersen EM, Green M, Pillai DR, Marquino W, Huilca M, Arevalo E, Garcia C, Solary L, Kain KC, Am J Trop Med Hyg 2003 69 548 552 14695094 (Pubitemid 38248258)
14. In-vivo sensitivity of Plasmodium vivax isolates from Rondonia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes MJ, Pereira da Silva LH, Ann Trop Med Parasitol 2000 94 749 758 10.1080/00034980020027960 11214093 (Pubitemid 32102485)
15. Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region. Alecrim MdG, Alecrim W, Macedo V, Rev Soc Bras Med Trop 1999 32 67 68 9927829 (Pubitemid 29006271)
16. Resistance to therapies for infection by Plasmodium vivax. Baird JK, Clinical Microbiol Rev 2009 22 508 534 10.1128/CMR.00008-09
17. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, Genton B, Beck HP, Felger I, J Infect Dis 2009 199 1074 1080 10.1086/597303 19275476
18. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q, J Infect Dis 2007 195 934 941 10.1086/512242 17330782 (Pubitemid 46452097)
19. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, Guthmann JP, Nosten F, Carlton J, Looareesuwan S, Nair S, Sudimack D, Day NP, Anderson TJ, White NJ, J Infect Dis 2007 195 927 933 10.1086/512241 17330781 (Pubitemid 46452096)
20. Chloroquine resistance in Plasmodium vivax. Baird JK, Antimicrob Agents Chemother 2004 48 4075 4083 10.1128/AAC.48.11.4075-4083.2004 15504824 (Pubitemid 39434858)
21. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, Prasetyorini B, Piera KA, Barends M, Brockman A, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN, PLoS ONE 2007 2 1089 10.1371/journal.pone.0001089 17971853 (Pubitemid 351566688)
22. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. de Pecoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK, Mol Biochem Parasitol 1998 92 265 273 10.1016/S0166-6851(97)00247-8 9657331 (Pubitemid 28248099)
23. Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand. Imwong M, Pukrittayakamee S, Cheng Q, Moore C, Looareesuwan S, Snounou G, White NJ, Day NP, Antimicrob Agents Chemother 2005 49 4393 4395 10.1128/AAC.49.10.4393-4395.2005 16189131 (Pubitemid 41400997)
24. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulphadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. Marfurt J dMF, Brega S, Barbollat L, Müller I, Reeder JC, Beck HP, Picot S, Genton B, J Infect Dis 2008 198 409 417 10.1086/589882 18582193
25. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Barnadas C, Ratsimbasoa A, Tichit M, Bouchier C, Jahevitra M, Picot S, Menard D, Antimicrob Agents Chemother 2008 52 4233 4240 10.1128/AAC.00578-08 18809933
26. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, Meshnick SR, Mugittu K, Naidoo I, Price RN, Shafer RW, Sibley CH, Sutherland CJ, Zimmerman PA, Rosenthal PJ, Malar J 2007 6 121 10.1186/1475-2875-6-121 17822535 (Pubitemid 47566322)
27. A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance. Carnevale EP, Kouri D, DaRe JT, McNamara DT, Mueller I, Zimmerman PA, J Clin Microbiol 2007 45 752 761 10.1128/JCM.01683-06 17121999 (Pubitemid 46427688)
28. Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Hastings MD, Maguire JD, Bangs MJ, Zimmerman PA, Reeder JC, Baird JK, Sibley CH, Antimicrob Agents Chemother 2005 49 733 740 10.1128/AAC.49.2.733-740.2005 15673758 (Pubitemid 40175687)
29. A trial of combination antimalarial therapies in children from Papua New Guinea. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett KF, Davis TM, NEJM 2008 359 2545 2557 10.1056/NEJMoa0804915 19064624
30. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A, Schopflin S, Stanisic D, Betuela I, Blood-Zikursh M, Siba P, Felger I, Schofield L, Zimmerman P, Mueller I, PLoS One 2010 5 9047 10.1371/journal.pone.0009047 20140220
31. Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. McNamara DT, Thomson JM, Kasehagen LJ, Zimmerman PA, J Clin Microbiol 2004 42 2403 2410 10.1128/JCM.42.6.2403-2410.2004 15184411 (Pubitemid 38747481)
32. Differentiating Plasmodium falciparum alleles by transforming Cartesian X,Y data to polar coordinates. DaRe JT, Kouri DP, Zimmerman PA, Thomas PJ, BMC Genetics 2010 11 57 20587031
33. Plasmodium vivax dhfr and dhps mutations in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine. Barnadas C, Tichit M, Bouchier C, Ratsimbasoa A, Randrianasolo L, Raherinjafy R, Jahevitra M, Picot S, Menard D, Malar J 2008 7 35 10.1186/1475-2875-7-35 18302746 (Pubitemid 351417047)
34. Antifolates can have a role in the treatment of Plasmodium vivax. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH, Trends Parasitol 2007 23 213 222 10.1016/j.pt.2007.03.002 17368986 (Pubitemid 46621225)
35. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP, Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G, Antimicrob Agents Chemother 2003 47 1514 1521 10.1128/AAC.47.5.1514-1521.2003 12709316 (Pubitemid 36548531)
36. Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, Cheng Q, Antimicrob Agents Chemother 2004 48 2214 2222 10.1128/AAC.48.6.2214-2222.2004 15155224 (Pubitemid 38691621)
37. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM, Antimicrob Agents Chemother 2002 46 3947 3953 10.1128/AAC.46.12.3947-3953.2002 12435700 (Pubitemid 35403273)
38. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, Sibley CH, Baird JK, J Infect Dis 2004 189 744 750 10.1086/381397 14767830 (Pubitemid 38270930)
39. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Marfurt J, Mueller I, Sie A, Maku P, Goroti M, Reeder JC, Beck HP, Genton B, Am J Trop Med Hyg 2007 77 947 954 17984359 (Pubitemid 351837847)
40. Genetic variations of the Plasmodium vivax dihydropteroate synthase gene. Menegon M, Majori G, Severini C, Acta Trop 2006 98 196 199 10.1016/j. actatropica.2006.03.003 16647679 (Pubitemid 43783138)
41. Characterization of treatment failure in Plasmodium vivax efficacy trials by genotyping neutral and drug resistance associated markers. Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TM, Mueller I, Antimicrob Agents Chemother 2011